image credit: Unsplash

Roche engaged in talks with FDA for Alzheimer’s drug candidate

July 23, 2021


CEO Severin Schwan told reporters on Thursday that Roche is in “a continued dialogue with the FDA. I wouldn’t be able to speculate what the outcome of this dialogue will be”.

He also revealed that Roche is planning to complete a phase 3 trial of the drug in the second half of 2022, adding that the “trial is a well-designed, very comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let’s keep fingers crossed”.

Read More on PMLiVE